What is a significant box warning associated with Apixaban?

Apixaban, an anticoagulant belonging to the direct Xa inhibitors class, carries a significant box warning regarding the increased risk of thrombotic events if the medication is discontinued prematurely. This warning is crucial because, when a patient stops taking Apixaban without proper transition to another anticoagulant, it can lead to serious complications, including the formation of blood clots. These thrombotic events can result in various serious conditions such as stroke or deep vein thrombosis, making it imperative for healthcare providers to ensure that patients understand the importance of adherence to their prescribed regimen and the risks associated with stopping treatment suddenly.

The other options do not accurately reflect the primary concerns associated with Apixaban. For instance, while renal function is essential in dosing at the right levels for Apixaban, the risk of renal failure is not highlighted as a box warning specifically for this medication. Possibility of addiction is not relevant, as Apixaban does not have addictive properties. Lastly, while overdosing on any medication can have serious implications, the specific box warning for Apixaban does not state cardiac arrest as a consequence, but rather focuses on the risk of thrombotic events related to premature discontinuation. This distinction underscores the importance of managing anticoagulation